Treatment of perianal fistulas with human embryonic stem cell-derived mesenchymal stem cells: A canine model of human fistulizing Crohn's disease

Regenerative Medicine

Volumn 11, Issue 1, 2016, Pages 33-43

  Ferrer, Lluís ^a   Kimbrel, Erin A ^b   Lam, Andrea ^a   Falk, Elizabeth B ^a   Zewe, Christine ^a   Juopperi, Tarja ^b   Lanza, Robert ^b   Hoffman, Andrew ^a  

^a TUFTS UNIVERSITY   (United States)

^b Ocata Therapeutics   (United States)

Author keywords

canine perianal furunculosis; Crohn's disease; human embryonic stem cells; mesenchymal stem cells; perianal fistulas; pluripotent stem cells

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 2; INTERLEUKIN 6; CYCLOSPORIN; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANUS FISTULA; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; DOG; EMBRYONIC STEM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; ANIMAL; BLOOD; CYTOLOGY; DISEASE MODEL; DOSE RESPONSE; FOLLOW UP; HUMAN EMBRYONIC STEM CELL; MESENCHYMAL STROMA CELL; RECTAL FISTULA; STROMA CELL; XENOGRAFT;

ANIMALS; CROHN DISEASE; CYCLOSPORINE; CYTOKINES; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HETEROGRAFTS; HUMAN EMBRYONIC STEM CELLS; HUMANS; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; RECTAL FISTULA; STROMAL CELLS;

EID: 84952690342     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.15.69     Document Type: Article

References (38)

1. Infammatory bowel disease: epidemiology of the IBD. http://www.cdc.gov/ibd/ibd-epidemiology.htm
2. Boyapati R, Satsangi J, Ho GT. Pathogenesis of Crohn's disease. F1000Prime Rep. 7, 44 (2015).
3. Marzo J, Felice C, Pugliese D et al. Management of perianal fstulas in Crohn's disease: an up-to-date review. World J. Gastroenterol. 21, 1394-1403 (2015).
4. Bourikas LA, Koutroubakis IE. Anti-TNF and fstulizing perianal Crohn's disease: use in clinical practice. Curr. Drug Targets 11(2), 187-197 (2011).
5. Houlton JE. Anal furunculosis: a review of seventy cases. J. Small Anim. Pract. 21(11): 25-33 (1980).
6. Day MJ, Weaver BM. Pathology of surgically resected tissue from 305 cases of anal furunculosis in the dog. J. Small Anim. Pract. 33(12), 583-589 (1992).
7. House A, Gregory SO, Catchpole B. Expression of cytokine mRNA in canine anal furunculosis lesions. Vet. Rec. 153(12), 354-358 (2003).
8. Mullin GE, Lazenby AJ, Harris ML et al. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 102(5), 1620-1627 (1992).
9. Desreumaux P, Brandt E, Gambiez L et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 113(1), 118-126 (1997).
10. Tivers MS, Catchpole B, Gregory S et al. Interleukin-2 and interferon-gamma mRNA expression in canine anal furunculosis lesions and the effect of ciclosporin therapy. Vet. Immunol. Immunopathol. 125(1-2), 31-35 (2008).
11. Mathews KA, Sukhiani HR. Randomized controlled trial of cyclosporine for treatment of perianal fstulas in dogs. J. Am. Vet. Med. Assoc. 211(10), 1249-1253 (1997).
12. House AK, Gregory SP, Catchpole B. Pattern-recognition receptor mRNA expression and function in canine monocyte/macrophages and relevance to canine anal furunculosis. Vet. Immunol. Immunopathol. 124(3-4), 230-240 (2008).
13. Massey J, Short AD, Catchpole B et al. Genetics of canine anal furunculosis. Immunogenetics 66 (5), 311-324 (2014).
14. Day M. Immunopathology of anal furunculosis in the dog. J. Small Anim. Pract. 34(8), 381-389 (1993).
15. Kennedy LJ, O'Neill T, House A et al. Risk of anal furunculosis in German shepherd dog is associated with the major histocompatibility complex. Tissue Antigens 71(1), 51-56 (2007).
16. Stanley BJ, Hauptman JG. Long-term prospective evaluation of topically applied 0.1% tacrolimus ointment for treatment of perinanal sinuses in dogs. J. Am. Vet. Med. Assoc. 235(4), 397-404 (2009).
17. Harkin KR, Walshaw R, Mullaney TP. Association of perianal fstula and colitis in the German shepherd dog: response to high-dose prednisone and dietary therapy. J. Am. Anim. Hosp. Assoc. 32(6), 515-520 (1996).
18. Jamieson PM, Simpson JW, Kirby BM et al. Association between anal furunculosis and colitis in the dog: preliminary observations. J. Small Anim. Pract. 43(3), 109-114 (2002).
19. Ciccocioppo R, Bernardo ME, Sgarella A et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fstulising Crohn's disease. Gut 60(6), 788-798 (2011).
20. Guadalajara H, Herreros D, De-La-Quintana P et al. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fstulas. Int. J. Colorrectal Dis. 27(5), 595-600 (2012).
21. Lee WY, Park KJ, Cho YB et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fstula. Stem Cells 31(11), 2575-2581 (2013).
22. Cho YB, Park KJ, Yoon SN et al. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn's fstula. Stem Cells Transl. Med. 4(5), 532-537 (2015).
23. Molendijk I, Bert A, Bonsing HR et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fstulas in patients with Crohn's disease. Gastroenterology doi:10.1053/j. gastro.2015.06.014 (2015) (Epub ahead of print).
24. Newman RE, Yoo D, LerOux MA et al. Treatment of infammatory diseases with mesenchymal stem cells. Infamm. Allergy Drug Targets 8 (2), 110-113 (2009).
25. Beane OS, Fonseca VC, Cooper LL et al. Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS ONE 9(12), e115963 (2014).
26. Wagner W, Horn P, Castoldi M et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS ONE 3(5), e2213 (2008).
27. Rombouts Wj, Ploemacher RE. Primary murine MSC show highly effcient homing to the bone marrow but lose homing ability following culture. Leukemia 17(1), 160-170 (2003).
28. Kyriakou C, Rabin N, Pizzey A et al. Factors that infuence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model. Haematologica 93(10), 1457-1465 (2008).
29. Li Z, Liu C, Xie Z et al. Epigenetic dysregulation in mesenchymal stem cell aging and spontaneous differentiation. PLoS ONE 6(6), e20526 (2011).
30. Kimbrel E, Kouris NA, Yavanian G et al. Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. Stem Cells Dev. 23(14), 1611-1624 (2014).
31. Wang X, Kimbrel EA, Ijichi K et al. Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. Stem Cell Rep. 3(1), 115-130 (2014).
32. Klimanskaya I, Chung Y, Becker S et al. Human embryonic stem cell lines derived from single blastomeres. Nature 444(7118), 481-485 (2006).
33. Patterson A, Kampbell KL. Managing anal furunculosis (perianal fstulas) in dogs. Compend. Small Anim. Pract. 27(3), 339-355 (2005).
34. Killingsworth CR, Walshaw R, Dunstan RW et al. Bacterial population and histologic changes in dogs with perianal fstula. Am. J. Vet. Res. 49(10), 1736-1741 (1988).
35. Reinisch W, Gasche C, Tillinger W et al. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am. J. Gastroenterol. 94(8), 2156-2164 (1999).
36. Ruffolo C, Scarpa M, Faggian D et al. Cytokine network in chronic perianal Crohn's disease and indeterminate colitis after colectomy. J. Gastrointest. Surg. 11(1), 16-21 (2007).
37. Ito H. Treatment of Crohn's disease with anti-IL-6 receptor antibody. J. Gastroenterol. 40 (Suppl. 16), 32-34 (2005).
38. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 380 (9853), 1590-1605 (2012).